Johnson & Johnson (JNJ) Exchange Rate Effect (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Exchange Rate Effect came in at -$25.0 million in Q1 2026, down 135.71% year-on-year from $70.0 million in Q1 2025, and down 208.7% quarter-over-quarter from $23.0 million in Q4 2025.
Johnson & Johnson (JNJ) Exchange Rate Effect (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Exchange Rate Effect across 18 years of filings, most recently posting -$25.0 million for Q1 2026.
- Exchange Rate Effect for Q1 2026 came in at -$25.0 million, down 135.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $106.0 million (up 212.77% YoY), and the FY2025 annual result was $201.0 million, up 169.55% from the prior year.
- Exchange Rate Effect came in at -$25.0 million for Q1 2026 at Johnson & Johnson, down from $23.0 million in the prior quarter.
- In the past five years, Exchange Rate Effect ranged from a high of $154.0 million in Q2 2025 to a low of -$198.0 million in Q4 2024.
- The 5-year median for Exchange Rate Effect is -$25.0 million (2026), against an average of -$26.4 million.
- Across the five-year window, Exchange Rate Effect sank 546.43% in 2024 and jumped 281.18% in 2025, its largest moves.
- Johnson & Johnson's Exchange Rate Effect stood at $16.0 million in 2022, then jumped by 681.25% to $125.0 million in 2023, then slumped by 258.4% to -$198.0 million in 2024, then jumped by 111.62% to $23.0 million in 2025, then plunged by 208.7% to -$25.0 million in 2026.
- The last three Exchange Rate Effect figures came in at -$25.0 million (Q1 2026), $23.0 million (Q4 2025), and -$46.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FX Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 2.70 Mn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 67.00 Mn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | -25.00 Mn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | -12.00 Mn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | -19.00 Mn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | -11.00 Mn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 19.00 Mn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | -48.00 Mn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - | -77.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | -25.00 Mn |
| Mar 29, 2026 | -25.00 Mn |
| Dec 28, 2025 | 23.00 Mn |
| Dec 28, 2025 | 23.00 Mn |
| Sep 28, 2025 | -46.00 Mn |
| Sep 28, 2025 | -46.00 Mn |
| Jun 29, 2025 | 154.00 Mn |
| Jun 29, 2025 | 154.00 Mn |
| Mar 30, 2025 | 70.00 Mn |
| Mar 30, 2025 | 70.00 Mn |
| Dec 29, 2024 | -198.00 Mn |
| Dec 29, 2024 | -198.00 Mn |
| Sep 29, 2024 | 119.00 Mn |
| Sep 29, 2024 | 119.00 Mn |
| Jun 30, 2024 | -85.00 Mn |
| Jun 30, 2024 | -85.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Mar 31, 2024 | -125.00 Mn |
| Dec 31, 2023 | 125.00 Mn |
| Dec 31, 2023 | 125.00 Mn |